Retatrutide, a novel dual-acting glucose-dependent incretin analog, represents a significant advance in peptide treatments for the management of type 2 sugar disorders and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor stimulant, offering